Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 10,850 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Moisture Management Liner Effectiveness Study

NCT04427007
Conditions
Amputation Stumps, Amputees, Amputation, Lower Limb Deformities, Congenital, Prosthesis User, Prosthesis
Interventions
Moisture Management Liner, Control Liner
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Holliston, Massachusetts
Conditions
Down Syndrome
Interventions
Body weight supported harness
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
Up to 2 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational

Scratching Validation Study

NCT05137093
Conditions
Atopic Dermatitis
Interventions
Actigraphy Device
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Maplewood, Missouri
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions
Alpha1-proteinase inhibitor, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

NCT02056301
Conditions
Pectus Excavatum
Interventions
Hydromorphone, Morphine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cystic Fibrosis
Interventions
Oral Glutathione, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more
Not listed Phase 4 Interventional

Triglyceride Lowering Study

NCT00934219
Conditions
Hypertriglyceridemia
Interventions
Omega-3-Acid Ethyl Esters
Drug
Lead sponsor
Jewish Hospital, Cincinnati, Ohio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Sickle Cell Disease, Quality of Life, Stigma, Social, Disease Self-Management
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

NCT02776098
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Primary Immunodeficiency Disorders
Interventions
Hizentra
Drug
Lead sponsor
University of South Florida
Other
Eligibility
1 Year to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St. Petersburg, Florida
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Budesonide in Calfactant
Drug
Lead sponsor
Cynthia McEvoy
Other
Eligibility
3 Days to 14 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Chris Goss
Other
Eligibility
2 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Palo Alto, California • Hartford, Connecticut • Washington D.C., District of Columbia + 23 more
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
2 Days to 12 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A, Docosahexaenoic acid, Control fatty acid
Dietary Supplement
Lead sponsor
Carol Weigel DiFranco
NIH
Eligibility
18 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed No phase listed Observational Accepts healthy volunteers

Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies

NCT04738539
Conditions
Myelomeningocele, Neurogenic Bladder, Tethered Cord Syndrome, Bladder, Neurogenic, Urologic Diseases, Neurologic Dysfunction
Interventions
Contrast Enhanced Voiding Urosonography with Urodynamic Testing, Urodynamic Testing
Drug · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
Up to 18 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
1 Day to 4 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease

NCT00787865
Conditions
Krabbe Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
zodasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Allopurinol, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
124
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
flow cytometry, laboratory biomarker analysis, Data Collection
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Recruiting No phase listed Observational Accepts healthy volunteers

Hemophilia A Research Program

NCT07414511
Conditions
Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency, Carrier of Hemophilia A, Inhibitors, Pregnancy, Maternal Blood Loss, Pregnancy Complications, Bleeding Disorder, Hemorrhage, Postpartum, Alloimmunization, X-Linked
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cystic Fibrosis
Interventions
urine lipoarabinomannan (LAM)
Diagnostic Test
Lead sponsor
Jerry A. Nick, M.D.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Denver, Colorado